Grace Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
GTx-104, an IV formulation of nimodipine for aSAH, demonstrated superior dose compliance, fewer hypotensive events, and better recovery outcomes versus oral forms in the STRIVE-ON trial. Regulatory review is progressing, with launch preparations focused on key hospitals and broad market education.
Fiscal Year 2025
-
A novel IV amlodipine formulation for subarachnoid hemorrhage demonstrated superior clinical and economic outcomes over oral therapy in a pivotal trial. With strong patent protection, focused commercialization, and FDA review underway, a major catalyst is expected by April 2026.
-
GTX-104, an IV nimodipine, demonstrated superior safety, neurological outcomes, and pharmacoeconomic benefits over oral nimodipine in subarachnoid hemorrhage. NDA submission is planned for mid-2024, with commercialization targeting high-volume stroke centers.
Fiscal Year 2024
-
GTx-104, an IV nimodipine, targets major limitations of oral therapy in aSAH, offering improved drug delivery, titratability, and operational flexibility. Experts anticipate strong adoption in stroke centers, with initial formulary restrictions likely to ease as clinical experience demonstrates benefits.
-
A novel IV formulation of nimodipine (GTX-104) aims to address significant limitations of oral therapy for aSAH, with a pivotal safety trial nearing full enrollment and NDA submission targeted for mid-2025. Strong hospital interest and a solid financial position support the program's progress.
-
GTX-104, a novel IV nimodipine, is advancing through a pivotal safety trial for subarachnoid hemorrhage, with NDA filing expected in early 2025. The product addresses major limitations of oral therapy, has strong market interest, and is supported by robust patent and orphan drug protections.